Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Seres Therapeutics Inc
(NQ:
MCRB
)
0.8198
+0.0370 (+4.73%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Seres Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Seres Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
February 27, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics’ Investigational SER-109 ECOSPOR IV Study Data Published in JAMA NETWORK OPEN
February 14, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Announces Initiation of Enrollment in SER-155 Phase 1b Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
February 08, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Recap: Seres Therapeutics Q3 Earnings
November 02, 2022
Seres Therapeutics (NASDAQ:MCRB) reported its Q3 earnings results on Wednesday, November 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 03, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 13, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Appoints Genomic Medicine and Microbiology Pioneer Claire M. Fraser, Ph.D., to its Board of Directors and Announces SER-155 Phase 1b Study Progress
January 05, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023
From
Seres Therapeutics, Inc.
Via
Business Wire
Charter Communications, Braze And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
December 14, 2022
U.S. stock futures traded slightly higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. iQIYI, Inc. (NASDAQ: IQ) shares dipped 14.1% to $3.31 in...
Via
Benzinga
Why Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarket
December 14, 2022
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares rose 150.9% to $0.6313 in pre-market trading after the company entered into a definitive merger agreement with GRI Bio.
Via
Benzinga
Seres Therapeutics to Host Investor Webcast on December 8, 2022 to Discuss SER-109 Commercial Strategy
November 22, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 02, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Host Third Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on November 2, 2022
October 27, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Why Pinterest Shares Jumped Around 14%; Here Are 69 Biggest Movers From Friday
October 31, 2022
Gainers Quanergy Systems, Inc. (NASDAQ: QNGY) jumped 153.9% to close at $3.30 on Friday.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
October 26, 2022
Gainers
Via
Benzinga
Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review
October 26, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics Presents SER-109 ECOSPOR IV Study Data at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meetings
October 23, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics’ ECOSPOR III Study Data on SER-109 Published in Journal of the American Medical Association
October 19, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Seres Therapeutics to Present Clinical Results at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meeting
October 12, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
September 20, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
September 20, 2022
Good morning, investor! It's time to start the day with a breakdown of the biggest pre-market stock movers for Tuesday morning!
Via
InvestorPlace
Ford, Evotec And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
September 20, 2022
U.S. stock futures traded lower this morning after recording gains in the previous session. Here are some big stocks moving lower in today’s pre-market trading session.
Via
Benzinga
Why O2Micro International Is Trading Higher By 7%; Here Are 25 Stocks Moving Premarket
September 20, 2022
Gainers
Via
Benzinga
Seres Therapeutics to Present at World Anti-Microbial Resistance Congress
September 08, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
Why IMARA Jumped Around 75%; Here Are 54 Biggest Movers From Yesterday
September 08, 2022
Gainers
Via
Benzinga
Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary
September 07, 2022
Via
Benzinga
Why Korn Ferry Is Trading Lower By Over 8%, Here Are 40 Stocks Moving In Wednesday's Mid-Day Session
September 07, 2022
Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 64% to $0.1199. Allena Pharmaceuticals shares dipped over 30% on Tuesday after the company announced it has filed for bankruptcy.
Via
Benzinga
Why Seres Therapeutics Shares Are Popping Off Today
September 07, 2022
Seres Therapeutics Inc (NASDAQ: MCRB) shares are trading higher by 13.24% to $6.12 Wednesday morning after the company announced it completed the rolling submission process for its BLA to the FDA for...
Via
Benzinga
Coupa Software, Glaukos And Some Other Big Stocks Moving Higher On Wednesday
September 07, 2022
Via
Benzinga
Seres Therapeutics Announces Completion of Rolling BLA Submission to FDA for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection
September 07, 2022
From
Seres Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.